Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 123

Similar articles for PubMed (Select 22653144)

1.

NT5E CpG island methylation is a favourable breast cancer biomarker.

Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T.

Br J Cancer. 2012 Jun 26;107(1):75-83. doi: 10.1038/bjc.2012.212. Epub 2012 May 31.

2.

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity.

Wang H, Lee S, Nigro CL, Lattanzio L, Merlano M, Monteverde M, Matin R, Purdie K, Mladkova N, Bergamaschi D, Harwood C, Syed N, Szlosarek P, Briasoulis E, McHugh A, Thompson A, Evans A, Leigh I, Fleming C, Inman GJ, Hatzimichael E, Proby C, Crook T.

Br J Cancer. 2012 Apr 10;106(8):1446-52. doi: 10.1038/bjc.2012.95. Epub 2012 Mar 27.

3.

Site-specific CpG methylation in the CCAAT/enhancer binding protein delta (CEBPδ) CpG island in breast cancer is associated with metastatic relapse.

Palmieri C, Monteverde M, Lattanzio L, Gojis O, Rudraraju B, Fortunato M, Syed N, Thompson A, Garrone O, Merlano M, Lo Nigro C, Crook T.

Br J Cancer. 2012 Aug 7;107(4):732-8. doi: 10.1038/bjc.2012.308. Epub 2012 Jul 10.

4.

Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.

Ramos EA, Camargo AA, Braun K, Slowik R, Cavalli IJ, Ribeiro EM, Pedrosa Fde O, de Souza EM, Costa FF, Klassen G.

BMC Cancer. 2010 Jan 28;10:23. doi: 10.1186/1471-2407-10-23.

6.

Methylation of the calcium channel regulatory subunit α2δ-3 (CACNA2D3) predicts site-specific relapse in oestrogen receptor-positive primary breast carcinomas.

Palmieri C, Rudraraju B, Monteverde M, Lattanzio L, Gojis O, Brizio R, Garrone O, Merlano M, Syed N, Lo Nigro C, Crook T.

Br J Cancer. 2012 Jul 10;107(2):375-81. doi: 10.1038/bjc.2012.231. Epub 2012 May 29.

7.

Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.

Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC Jr, Yu Y.

Cancer Res. 2003 Jul 15;63(14):4174-80.

9.

Primary tumor classification according to methylation pattern is prognostic in patients with early stage ER-negative breast cancer.

van Hoesel AQ, van de Velde CJ, Kuppen PJ, Putter H, de Kruijf EM, van Nes JG, Giuliano AE, Hoon DS.

Breast Cancer Res Treat. 2012 Feb;131(3):859-69. doi: 10.1007/s10549-011-1485-3. Epub 2011 Apr 11.

PMID:
21479925
10.

Promoter CpG island hypermethylation during breast cancer progression.

Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, Kang GH.

Virchows Arch. 2011 Jan;458(1):73-84. doi: 10.1007/s00428-010-1013-6. Epub 2010 Dec 1.

PMID:
21120523
11.

GATA5 CpG island methylation in renal cell cancer: a potential biomarker for metastasis and disease progression.

Peters I, Eggers H, Atschekzei F, Hennenlotter J, Waalkes S, Tränkenschuh W, Grosshennig A, Merseburger AS, Stenzl A, Kuczyk MA, Serth J.

BJU Int. 2012 Jul;110(2 Pt 2):E144-52. doi: 10.1111/j.1464-410X.2011.10862.x. Epub 2012 Jan 30.

PMID:
22289415
12.

The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.

Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Dürst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E.

Oncogene. 2008 Jan 31;27(6):865-76. Epub 2007 Jul 23.

PMID:
17653090
13.

Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and Dickkopf-3 (DKK3) promoter methylation in human breast cancer.

Veeck J, Wild PJ, Fuchs T, Schüffler PJ, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2009 Jul 1;9:217. doi: 10.1186/1471-2407-9-217.

14.
15.

Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer.

Akhoondi S, Lindström L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grandér D, Sangfelt O.

Breast Cancer Res. 2010;12(6):R105. doi: 10.1186/bcr2788. Epub 2010 Dec 1.

16.

Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.

Chung W, Kwabi-Addo B, Ittmann M, Jelinek J, Shen L, Yu Y, Issa JP.

PLoS One. 2008 Apr 30;3(4):e2079. doi: 10.1371/journal.pone.0002079. Erratum in: PLoS ONE. 2008;3(5). doi: 10.1371/annotation/2548989f-1f13-4ea5-8af8-62420b0a590e.

17.

5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer.

Zöchbauer-Müller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchgrub S, Gazdar AF, Minna JD.

Cancer Res. 2001 May 1;61(9):3581-5.

18.

Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer.

Yan PS, Shi H, Rahmatpanah F, Hsiau TH, Hsiau AH, Leu YW, Liu JC, Huang TH.

Cancer Res. 2003 Oct 1;63(19):6178-86.

19.

Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse.

Noetzel E, Rose M, Sevinc E, Hilgers RD, Hartmann A, Naami A, Knüchel R, Dahl E.

Oncogene. 2010 Aug 26;29(34):4814-25. doi: 10.1038/onc.2010.229. Epub 2010 Jun 14.

PMID:
20543860
20.

ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.

Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, Del Moral R, Ruiz De Almodóvar JM, Menjón S, Concha A, Chamorro C, Ríos S, Delgado JR.

BMC Cancer. 2014 Feb 4;14:59. doi: 10.1186/1471-2407-14-59.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk